Sunshine Biopharma advances lead coronavirus drug candidate into IND-enabling studies
SBFM•Lead coronavirus candidate enters IND-enabling studies
Sunshine Biopharma moved its lead coronavirus drug candidate into IND-enabling studies on September 16, 2026.
The candidate showed nanomolar in vitro potency against PLpro with broad activity across SARS-CoV-2 variants.
Preclinical data showed oral bioavailability and lung enrichment
Animal studies indicated strong oral bioavailability in mice, rats and dogs, with preferential lung enrichment in mice and rats.
In K18-hACE2 mice infected with SARS-CoV-2, repeated oral dosing cut pulmonary viral replication in a dose-dependent manner.
